The route to new therapeutics often ends in costly failure. The secret of success is the rapid and accurate identification of drug targets with true potential, says Caitlin Smith.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Author notes
Caitlin Smith is a science writer based in Portland, Oregon.
- Caitlin Smith
Rights and permissions
About this article
Cite this article
Smith, C. Drug target validation: Hitting the target. Nature 422, 342–345 (2003). https://doi.org/10.1038/422341a
Issue date:
DOI: https://doi.org/10.1038/422341a
